Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I did some research 10 yrs back when I thought the FDA was going to do something about all the opioid abuse.
FDA decided to not do much and ignore it and LET it take care of it self
They had the option to make all opioids ADF and start just giving quota for the ADFs and slowly decrease non ADF opioids.
The drug dealer has lost most of his older customers over the years
Most people can not afford to take as many pills as they want.
Most people try to get high on one pill at a time by chewing snorting or injecting. It will make the bottle last much longer.
iF they have an endless supply of drug they can take it by the handfuls. No ADF will help that situation at this time. The drug dealer near me sells one or two pills at a time unless he has a rich customer.
Wezul had some good ideas about how stop that.
Hope this helps.
Hope Nasrat revisits the unique ADF without naltrexone that was ran in trials along side of the new and improved SequestOx
Who sent you? And why ?
Thxs How did you find this out. ?
We know about the buyout time line of 2 years, but not the who.
TIA
jammy32
Another day of disappointment coming up here
Good luck .
Hope all is better. I did not see this post till Feb 29th
23 month to BuyOut :
X 1. Cash Flow Positive Status - 5 years
X 2. Purchase main building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirkov, Doug and the Team
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. $50 million in yearly revenues
__13. Generate revenues over $20 million/quarter
__14. Generic OxyContin Approval -;FIRST TO FILE Aug 17, 2023 $720 Million
__15. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
X 16. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs Jan 2024
__17. European distribution - Dexcel partnership approval by Israeli Health
__18. Full ownership of Adderall IR $ 335 Million
__19. Full ownership of Adderall XR $ 1.56 Billion
__20. Generic Concerta- $1.2 BILLION FDA submission
__21. Vigabatrin - VigPoder approved Pyros $233 Million trade mark challenge
__22. $100 million in yearly revenues
__23. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
__24. Patented Unique ADF (w/o naltrexone)-- NDA
__25. Mikah ANDA (s)
__26. Undisclosed ANDAs/NDAs
__27. Antimetabolite ANDA- Methotrexate -$600 Million - unconfirmed
__28. Undisclosed Antimetabolite ANDA- $42 Million
__29. Generic Vyvanse Approval
__30. DollarLand PPS
__31. Uplist to the NASDAQ Exchange
__32. ELTP Elite Pharmaceutical Buyout - less than 2 1/2 years from Feb 2024
__33. Vegas Baby !!!!!!!
Stop losses were takin’ out last bear run.
BuyOut price rising as we get closer to The 2 year event.
Where between $2 and $4 will it end up ?
What is a conservative 5% of combined $10 billion IMS markets worth to the Acquiring entity ?
It’s going to Get Real in a hurry
Enjoy the Ride!
ELTP
Dang !!!!! How many Tickers do you bash??
WE have the opportunity to purchase the other half of adderall ownership.
Probably would not if another Pharma bought it.
Buy one at a time IR or ER to spread out the purchase and ease the burden
E
L
T
P
You guys sound stressed 😆
The Unicorn of The OTC:
ELTP
X 1. Cash Flow Positive Status - 4 + years
X 2. Purchase building which houses their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirkov
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. Generate revenues over $20 million/quarter
__13. Generic OxyContin Approval -;FIRST TO FILE Aug 17, 2023 $720 Million
__14. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
X 15. Lease additional manufacturing and storage space for new ANDAs Jan 2024 - 34,000 square foot 18+ ft ceilings
__16. European distribution Dexcel partnership approval by Israeli Health
__17. Full ownership of Adderall IR $ 335 Million
__18. Full ownership of Adderall XR $ 1.56 Billion
__19. Generic Concerta- $1.2 BILLION FDA submission
__20. Vigabatrin - VigPoder approved Pyros $233 Million trade mark challenge
__21. $100 million in yearly revenues
__22. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
__23. Patented Unique ADF (w/o naltrexone)-- NDA
__24. Mikah ANDA (s)
__25. Undisclosed ANDAs/NDAs
__26. Antimetabolite ANDA- Methotrexate -$600 Million
__27. Undisclosed Antimetabolite ANDA- $42 Million
__28. Generic Vyvanse Approval
__29. DollarLand PPS
__30. Uplist to the NASDAQ Exchange
__31. THE Buy Out ! 2.0-2.5 yrs from Feb 2024
__32. Vegas Baby !!!!!!! 2.5 yrs
Bullish
We could sell unused ANDAs back to Mikah as part of the Adderall buy back.
Congrats
Post history can’t be covered up.
Buyout price now is well above $0.16.
The share price does not have anything to do with buyout.
Projected revenues 7 years from now or 5 years out from Buyout is what matters.
Ever think to ask SunGen ?
It would only reduce the buyout price by $0.30 not enough to worry at $3-4 dollars/ share
HammerTime !!!!!!!!!!!!!!!!!
The Unicorn of The OTC:
ELTP
X 1. Cash Flow Positive Status - 4 + years
X 2. Purchase building which houses their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirkov
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. Generate revenues over $20 million/quarter
__13. Generic OxyContin Approval -;FIRST TO FILE Aug 17, 2023 $720 Million
__14. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
X 15. Lease additional manufacturing and storage space for new ANDAs Jan 2024 - 34,000 square foot 18+ ft ceilings
__16. European distribution Dexcel partnership approval by Israeli Health
__17. Full ownership of Adderall IR $ 335 Million
__18. Full ownership of Adderall XR $ 1.56 Billion
__19. Generic Concerta- $1.2 BILLION FDA submission
__20. Vigabatrin - VigPoder approved Pyros $233 Million trade mark challenge
__21. $100 million in yearly revenues
__22. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
__23. Patented Unique ADF (w/o naltrexone)-- NDA
__24. Mikah ANDA (s)
__25. Undisclosed ANDAs/NDAs
__26. Antimetabolite ANDA- Methotrexate -$600 Million
__27. Undisclosed Antimetabolite ANDA- $42 Million
__28. Generic Vyvanse Approval
__29. DollarLand PPS
__30. Uplist to the NASDAQ Exchange
__31. THE Buy Out ! 2.0-2.5 yrs from Feb 2024
__32. Vegas Baby !!!!!!! 2.5 yrs
Glad you finally took on a few a while back
Congrats
Thx for yesterdays buying Op
Patience is paying off.
JL renewed subscription till BuyOut
2011 is a long time to sit pretty. LOL
Ive been sitting pretty since the HammerBottom
SAME HERE !!
MM shaking the trees, Longs raking up the leaves $$$$$$$$$
\
ELTP
Great move.
GLTY
ELTP
Are you flippin at $0.97 again or going all the way to THE BUYOUT ?
ELTP
I’m accumulating for The buyout too.
GLTY
Gem of The OTC:
ELTP
X 1. Cash Flow Positive Status - 4 + years
X 2. Purchase building which houses their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirkov
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. Generate revenues over $20 million/quarter
__13. Generic OxyContin Approval -;FIRST TO FILE Aug 17, 2023 $720 Million
__14. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
X 15. Lease additional manufacturing and storage space for new ANDAs Jan 2024 - 34,000 square foot 18+ ft ceilings
__16. European distribution Dexcel partnership approval by Israeli Health
__17. Full ownership of Adderall IR $ 335 Million
__18. Full ownership of Adderall XR $ 1.56 Billion
__19. Generic Concerta- $1.2 BILLION FDA submission
__20. Vigabatrin - VigPoder approved Pyros $233 Million trade mark challenge
__21. $100 million in yearly revenues
__22. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
__23. Patented Unique ADF (w/o naltrexone)-- NDA
__24. Mikah ANDA (s)
__25. Undisclosed ANDAs/NDAs
__26. Antimetabolite ANDA- Methotrexate -$600 Million
__27. Undisclosed Antimetabolite ANDA- $42 Million
__28. Generic Vyvanse Approval
__29. DollarLand PPS
__30. Uplist to the NASDAQ Exchange
__31. THE Buy Out ! 2.0-2.5 yrs from Feb 2024
__32. Vegas Baby !!!!!!! 2.5 yrs
HammerTime !
$$$$$$
These fluctuations don’t affect the CEOs buyout price 2 years down the road from now.
The price will be based on predicted revenues as far out as 7 years from today or 5 years out at buyout date.
How much of the combined $10 billion dollar IMS markets can be achieved will be key.
That $10 billion combined IMS market will grow once all the needle movers and undisclosed monsters are revealed.
A new Co. valuation will be used in the negotiations as well.
Exciting times ahead woot woot !
Don’t lose site of the big picture ahead.
The Accumulation for The Buyout Continues till about a year before buyout for traditional trading accounts to minimize short term capital gains. For trad and Roth IRAs we can buy all the way to the Big Day
Anyone living in a non tax friendly place has time to establish new residence if needed to minimize tax burden. CEO gave us a big heads up so we can prepare.
Locked $ Loaded
ELTP
I think you meant excited ?
What’s not to be excited about.
HammerBottom well in the rear view.
Big week coming up.
Enjoying the ride to THE BUYOUT ?
We will check off another 7-9 items off before years end.
Huge funds coming Tuesday
Hope to beat any monster news.
Your 10 year wait is over.
GL
Unicorn of the OTC:
ELTP
X 1. Cash Flow Positive Status - 4 years
X 2. Purchase main building which houses their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirkov
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. Generate revenues over $20 million/quarter
__13. Generic OxyContin Approval -;FIRST TO FILE Aug 17, 2023 $720 Million
__14. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
X 15. Lease additional manufacturing and storage space for new ANDAs Jan 2024 - 5 years 34,000 square foot 18+ ft ceilings
__16. European distribution Dexcel partnership approval by Israeli Health
__17. Full ownership of Adderall IR $ 335 Million
__18. Full ownership of Adderall XR $ 1.56 Billion
__19. Generic Concerta- $1.2 BILLION FDA submission
__20. Vigabatrin - VigPoder approved Pyros $233 Million trade mark challenge
__21. $100 million in yearly revenues
__22. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
__23. Patented Unique ADF (w/o naltrexone)-- NDA
__24. Mikah ANDA (s)
__25. Undisclosed ANDAs/NDAs
__26. Antimetabolite ANDA- Methotrexate -$600 Million
__27. Undisclosed Antimetabolite ANDA- $42 Million
__28. Generic Vyvanse Approval
__29. DollarLand PPS
__30. Uplist to the NASDAQ Exchange
__31. THE Buy Out ! 2.0-2.5 yrs from Feb 2024
__32. Vegas Baby !!!!!!! 2.5 yrs
Dexcel commercializes branded and generic pharmaceutical products globally via a network of affiliates, distributors, and partners. We recognize market-specific needs and quickly identify local opportunities. Our key markets are the United States, Israel, Germany, the United Kingdom, and Austria.
THANK YOU for the UpDate !
ELTP
LOL
We have two potential ANDAs that could be approved by months end or soon after.
Buyout between $1.51 and $3.11 in 2years.
Get your chickens in a row.
Is it possible to Minimize your tax liabilities in your country.
Do it within 2 years to play it safe.
GLTY
$$$$$$$$$$$$